AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18566549 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered in the same manner as SLIT.
Number of subjects: 61
Study 18566549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized Japanese cedar extract
Number of subjects: 61
Study 16641354 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0-T MR imaging
Number of subjects: 48
Study 16641354 — intervention group
Group type: COMPARATOR
Intervention: 1.5-T MR imaging
Number of subjects: 48
Study 12918150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Tegafur plus intravesical mitomycin
Number of subjects: 80
Study 12918150 — intervention group
Group type: COMPARATOR
Intervention: Intravesical mitomycin alone
Number of subjects: 80
Study 10463903 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8600872 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental seat (TCS)
Number of subjects: 47
Study 8600872 — intervention group
Group type: COMPARATOR
Intervention: Standard cushions (control)
Number of subjects: 47
Study 1752150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients with delayed gastric emptying (GET)
Number of subjects: 31
Study 1752150 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus patients with normal GET
Number of subjects: 31
Study 1752150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients with delayed GET
Number of subjects: 31
Study 1752150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients
Number of subjects: 31
Study 6890537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BCG
Number of subjects: 244
Study 6890537 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen F (soluble cytoplasmic components of M. tuberculosis, M. aquae, and M. lepraemurium)
Number of subjects: 244
Study 6890537 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen G (soluble cytoplasmic components of M. piscium and M. balnei)
Number of subjects: 244
Study 6890537 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen H (soluble cytoplasmic components of M. leprae)
Number of subjects: 244
Study 6890537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 31519504 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractive video during local anesthetic administration
Number of subjects: 115
Study 31519504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distractive video)
Number of subjects: 115
Study 28647677 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (2–4 mg; sublingual)
Number of subjects: 43
Study 28647677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablets with identical shape, color, consistency, and scent)
Number of subjects: 43
Study 26395873 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherhood decision aid (DA)
Number of subjects: 144
Study 26395873 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 23717406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention (patient education, support at the hospital, improved communication between treating and occupational physicians, and organizing a meeting for a gradual return-to-work plan)
Number of subjects: 133
Study 23717406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention
Number of subjects: 133
Study 23717406 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 133
Study 21343153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track (FT) care
Number of subjects: 99
Study 21343153 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (TC)
Number of subjects: 99
Study 19139383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifalazil 25 mg once weekly for 8 weeks
Number of subjects: 297
Study 19139383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 19139383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifalazil
Number of subjects: 297
Study 19139383 — intervention group
Group type: COMPARATOR
Intervention: Rifalazil and Placebo
Number of subjects: 297
Study 18007568 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive risperidone
Number of subjects: 417
Study 18007568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 14964587 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy and stretch
Number of subjects: 30
Study 14964587 — intervention group
Group type: COMPARATOR
Intervention: Sham diathermy and stretch
Number of subjects: 30
Study 14964587 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 11755953 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin administered 12 hours before and 12 hours after surgery, then once daily for 7 days
Number of subjects: 0
Study 11755953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 11051950 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care education project for nursing home staff
Number of subjects: 0
Study 11051950 — intervention group
Group type: COMPARATOR
Intervention: Non-participating nursing homes
Number of subjects: 0
Study 9510925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate supplementation for 4 weeks
Number of subjects: 100
Study 9510925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 100
Study 8457049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms/ml with bupivacaine 0.01% and epinephrine 0.5 micrograms/ml
Number of subjects: 250
Study 8457049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.8 micrograms/ml with bupivacaine 0.01% and epinephrine 0.5 micrograms/ml
Number of subjects: 250
Study 8457049 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 250
Study 3086024 — intervention group
Group type: EXPERIMENTAL
Intervention: 51Cr‐labelled ethylenediaminetetra‐acetate (51Cr‐EDTA)
Number of subjects: 0
Study 3086024 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethyleneglycol 400 (PEG‐400)
Number of subjects: 0
Study 3086024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar stress
Number of subjects: 0
Study 29240023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathode tDCS
Number of subjects: 12
Study 29240023 — intervention group
Group type: COMPARATOR
Intervention: Anode tDCS
Number of subjects: 12
Study 29240023 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study 27716690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg loading dose over 15 min, maintained at 0.3 μg/kg/h)
Number of subjects: 150
Study 27716690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 150
Study 24249435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day, 28 days on and 14 days off)
Number of subjects: 54
Study 24249435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 24249435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 54
Study 24249435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (post-placebo progression)
Number of subjects: 54
Study 22447964 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-directed therapy (prednisolone or matching placebo based on blood eosinophil count)
Number of subjects: 166
Study 22447964 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (prednisolone for 2 weeks)
Number of subjects: 166
Study 22447964 — intervention group
Group type: COMPARATOR
Intervention: Placebo in biomarker-negative exacerbations
Number of subjects: 166
Study 22447964 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone in biomarker-negative exacerbations
Number of subjects: 166
Study 21083889 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab, 100 mg plus placebo
Number of subjects: 336
Study 21083889 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab, 50 mg plus MTX
Number of subjects: 336
Study 21083889 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab, 100 mg plus MTX
Number of subjects: 336
Study 21083889 — intervention group
Group type: COMPARATOR
Intervention: placebo plus MTX
Number of subjects: 336
Study 18771050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha2b (1.0 microg/kg/week) plus ribavirin (800-1,200 mg/day) for 48 weeks
Number of subjects: 93
Study 18771050 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interferon-alpha2b (3 million IU three times/week) plus ribavirin (800-1,200 mg/day) for 48 weeks
Number of subjects: 93
Study 15645383 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB) with 20 ml bupivacaine 0.5 % + 60 ml prilocaine 1 %
Number of subjects: 99
Study 15645383 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia (EA) with 12 ‐ 20 ml bupivacaine 0.5 %
Number of subjects: 99
Study 15645383 — intervention group
Group type: EXPERIMENTAL
Intervention: PNB
Number of subjects: 99
Study 15645383 — intervention group
Group type: COMPARATOR
Intervention: EA
Number of subjects: 99
Study 12020336 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic shoes with customized medium-density cork inserts (n = 121)
Number of subjects: 400
Study 12020336 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic shoes with prefabricated, tapered polyurethane inserts (n = 119)
Number of subjects: 400
Study 12020336 — intervention group
Group type: COMPARATOR
Intervention: Usual footwear (controls; n = 160)
Number of subjects: 400
Study 12020336 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic shoes (both insert types)
Number of subjects: 400
Study 10537441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine added to zidovudine-containing regimens for 1 year
Number of subjects: 1840
Study 10537441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine added to zidovudine-containing regimens
Number of subjects: 1840
Study 8620704 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodinated glycerol (IG) 60 mg qid for 16 weeks
Number of subjects: 26
Study 8620704 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 26
Study 8620704 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodinated glycerol (IG)
Number of subjects: 26
Study 8620704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8620704 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodinated glycerol (IG) and Placebo
Number of subjects: 26
Study 2013587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (5000 international units once daily)
Number of subjects: 136
Study 2013587 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (5000 international units three times a day)
Number of subjects: 136
Study 2013587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 136
Study 2013587 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 136
Study 29932311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg daily
Number of subjects: 296
Study 29932311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 27100801 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular CAF
Number of subjects: 50
Study 27100801 — intervention group
Group type: COMPARATOR
Intervention: Trapezoidal CAF
Number of subjects: 50
Study 27100801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of CAF
Number of subjects: 50
Study 24504788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports bag (with logo)
Number of subjects: 80
Study 24504788 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier load (5 kg)
Number of subjects: 80
Study 24504788 — intervention group
Group type: COMPARATOR
Intervention: School bag and neutral bag
Number of subjects: 80
Study 21728454 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distance intervention
Number of subjects: 0
Study 19921097 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative use of 0.2% chlorhexidine gluconate rinse (CHX)
Number of subjects: 28
Study 19921097 — intervention group
Group type: COMPARATOR
Intervention: No postoperative use of chlorhexidine rinse (Control)
Number of subjects: 28
Study 18573149 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer
Number of subjects: 55
Study 18573149 — intervention group
Group type: COMPARATOR
Intervention: Acid gel, semi-gel, low-viscosity gel, liquid
Number of subjects: 55
Study 16873786 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 476
Study 16873786 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 476
Study 12851181 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tube feeding
Number of subjects: 105
Study 12851181 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus tube feeding
Number of subjects: 105
Study 10793593 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 0.5 mg kg‐1 (group K1)
Number of subjects: 49
Study 10793593 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 1.0 mg kg‐1 (group K2)
Number of subjects: 49
Study 10793593 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine with epinephrine 1:200,000 (group B)
Number of subjects: 49
Study 8632221 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial phytase from Aspergillus niger added to phytase-deactivated wheat bran
Number of subjects: 10
Study 8632221 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran with phytase activity
Number of subjects: 10
Study 1425626 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ondansetron
Number of subjects: 500
Study 1425626 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 500
Study 1425626 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 500
Study 1425626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 1425626 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ondansetron
Number of subjects: 500
Study 3855413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice A (1000 ppm F as Na2PO3F + 450 ppm F as NaF)
Number of subjects: 22
Study 3855413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice B (1100 ppm F as NaF)
Number of subjects: 22
Study 3855413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice C (1000 ppm F as Na2PO3F)
Number of subjects: 22
Study 3855413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice D (1000 ppm F as SnF2)
Number of subjects: 22
Study 3855413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice E (1500 ppm F as Na2PO3F)
Number of subjects: 22
Study 3855413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 ppm F)
Number of subjects: 22
Study 30016396 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily remote monitoring
Number of subjects: 664
Study 30016396 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 664
Study 29555496 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning tool in addition to standard patient education
Number of subjects: 416
Study 29555496 — intervention group
Group type: COMPARATOR
Intervention: standard patient education
Number of subjects: 416
Study 25526969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation for 30 days
Number of subjects: 20
Study 25526969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24444325 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsory community treatment
Number of subjects: 5444
Study 24444325 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5444
Study 23255861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree oil eyelid scrub (TTO)
Number of subjects: 106
Study 23255861 — intervention group
Group type: COMPARATOR
Intervention: Without tea tree oil (Control group)
Number of subjects: 106
Study 19997983 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fundoplication anastomosis
Number of subjects: 56
Study 19997983 — intervention group
Group type: COMPARATOR
Intervention: Conventional end of esophagus to side of gastric conduit anastomosis
Number of subjects: 56
Study 17391302 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) - 20 mg doxycycline twice daily
Number of subjects: 50
Study 17391302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17391302 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD)
Number of subjects: 50
Study 16241013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg) 2 hours before the procedure
Number of subjects: 87
Study 16241013 — intervention group
Group type: COMPARATOR
Intervention: Paracervical block
Number of subjects: 87
Study 12463579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 7433
Study 12463579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (administered not earlier than 6 hours postoperatively)
Number of subjects: 7433
Study 12463579 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 7433
Study 9526145 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Availability (told they could smoke shortly)
Number of subjects: 132
Study 9526145 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Stimuli (presence of smoking-related stimuli)
Number of subjects: 132
Study 9526145 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe reaction time (presence of smoking stimuli)
Number of subjects: 132
Study 7607964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (HF XRT) with chemotherapy, total radiation dose of 59.4 Gy, in 1.10 Gy fractions, twice daily at 6‐8 h intervals.
Number of subjects: 332
Study 7607964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (HF XRT) with chemotherapy
Number of subjects: 332
Study 2359574 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring plus perinatal nursing support
Number of subjects: 0
Study 2359574 — intervention group
Group type: COMPARATOR
Intervention: Preterm birth prevention program including intensive education and more frequent prenatal visits
Number of subjects: 0
Study 274808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealing with diluted composite material on etched surfaces
Number of subjects: 0
Study 274808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealing with diluted composite material on etched-fluoridated surfaces
Number of subjects: 0
Study 274808 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (not specified intervention)
Number of subjects: 0
Study 274808 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall fissure sealing
Number of subjects: 0
Study 31244293 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative concurrent chemoradiation (CCRT)
Number of subjects: 139
Study 31244293 — intervention group
Group type: COMPARATOR
Intervention: Post-operative radiation (RT) alone
Number of subjects: 139
Study 28663317 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg prednisolone daily for 10 days
Number of subjects: 55
Study 28663317 — intervention group
Group type: EXPERIMENTAL
Intervention: six-gene expression biomarker signature
Number of subjects: 55
Study 28663317 — intervention group
Group type: EXPERIMENTAL
Intervention: six-gene expression signature including eosinophil and Th2 related mast cell biomarkers
Number of subjects: 55
Study 25288047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheo Knee() II
Number of subjects: 10
Study 25288047 — intervention group
Group type: COMPARATOR
Intervention: non‐microprocessor controlled prosthetic knee
Number of subjects: 10
Study 24103283 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP group A (0-1 mmHg)
Number of subjects: 97
Study 24103283 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP group B (1.1-2 mmHg)
Number of subjects: 97
Study 24103283 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP group C (2.1-3 mmHg)
Number of subjects: 97
Study 24103283 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP group D (3.1-4 mmHg)
Number of subjects: 97
Study 24103283 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP group E (4.1-5 mmHg)
Number of subjects: 97
Study 24103283 — intervention group
Group type: COMPARATOR
Intervention: CVP groups A, B, and C
Number of subjects: 97
Study 24103283 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP groups A and B
Number of subjects: 97
Study 22052139 — intervention group
Group type: EXPERIMENTAL
Intervention: RhG‐CSF administered as a subcutaneous single dose of 10 μg/kg
Number of subjects: 40
Study 22052139 — intervention group
Group type: COMPARATOR
Intervention: RhG‐CSF administered as 10 μg/kg/s.c./day once daily for 3 days
Number of subjects: 40
Study 19536424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramiprosate 100 mg BID
Number of subjects: 508
Study 19536424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramiprosate 150 mg BID
Number of subjects: 508
Study 19536424 — intervention group
Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 508
Study 16585294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sites (adherence to CDC recommendations)
Number of subjects: 2584
Study 16585294 — intervention group
Group type: COMPARATOR
Intervention: Control sites (non-adherence to CDC recommendations)
Number of subjects: 2584
Study 16585294 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence to CDC recommendations
Number of subjects: 2584
Study 16585294 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to CDC recommendations for second episode
Number of subjects: 2584
Study 12559144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (distraction and reappraisal) with information pre-operatively
Number of subjects: 48
Study 12559144 — intervention group
Group type: COMPARATOR
Intervention: Control group (information alone)
Number of subjects: 48
Study 12559144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48